secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOXYTRAN, INC (BIXT)
CIK:        0001445815
Form:       8-K
Filed at:   2025-01-13T23:59:59+00:00
Accession:  0001493152-25-001891
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 4.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioXytran restates 2022-2023 financials on share valuation errors; non-reliance on prior filings
--------------------------------------------------------------------------------

- Net loss for 2023 increased by $192,523 to $4.56M; for 2022 increased by $9,202 to $2.67M.
- Restatement driven by misvaluation of shares under Rule 3(a)(9) and Rule 701, and timing errors in accruals.
- Company engaged Fruci & Associates as successor auditor after SEC denied BF Borgers privilege.
- Common stock adjusted (1M shares returned to treasury in 2023; 93,750 shares added in 2022).
- No net impact on cash flows from operations, investing, or financing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1445815/000149315225001891/0001493152-25-001891-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1445815/000149315225001891/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-001891

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer